(Q74841396)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9692108%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

title

Phase II trial of intrapleural paclitaxel injection for non-small-cell lung cancer patients with malignant pleural effusions (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9692108%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

main subject

phase II clinical trial

1 reference

1 reference

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9692108%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

author name string

R P Perng

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9692108%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

Y M Chen

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9692108%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

K C Chou

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9692108%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

W C Lin

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9692108%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

J M Liu

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9692108%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

J Whang-Peng

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9692108%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

publication date

1 March 1998

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9692108%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9692108%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

volume

92

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9692108%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9692108%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

page(s)

473-479

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9692108%20AND%20SRC:MED&resulttype=core&format=json

The malignant pleural effusion. A review of cytopathologic diagnoses of 584 specimens from 472 consecutive patients

13 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2898%2990294-3

7 January 2021

Carcinomatous involvement of the pleura: an analysis of 96 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2898%2990294-3

7 January 2021

Malignant pleural effusions. A clinical cytopathologic study

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2898%2990294-3

7 January 2021

Primary carcinoma of the lung. A review of 417 histologically proved cases.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2898%2990294-3

7 January 2021

Chemical pleurodesis for malignant pleural effusions

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2898%2990294-3

7 January 2021

Management of malignant pleural effusions

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2898%2990294-3

7 January 2021

Intrapleural cisplatin and cytarabine in the management of malignant pleural effusions: a Lung Cancer Study Group trial

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2898%2990294-3

7 January 2021

A comparative trial of LC9018 plus doxorubicin and doxorubicin alone for the treatment of malignant pleural effusion secondary to lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2898%2990294-3

7 January 2021

Intracavitary chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2898%2990294-3

7 January 2021

Dose-intense taxol: high response rate in patients with platinum-resistant recurrent ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2898%2990294-3

7 January 2021

Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2898%2990294-3

7 January 2021

Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2898%2990294-3

7 January 2021

Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2898%2990294-3

7 January 2021

Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: The Eastern Cooperative Oncology Group Results

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2898%2990294-3

7 January 2021

Phase I trial of intraperitoneal taxol: a Gynecoloic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2898%2990294-3

7 January 2021

A phase I feasibility and pharmacokinetic study of intrapleural paclitaxel in patients with malignant pleural effusions

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2898%2990294-3

7 January 2021

Thoracoscopic talc poudrage pleurodesis for chronic recurrent pleural effusions

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2898%2990294-3

7 January 2021

Management of recurrent malignant pleural effusions. The complementary role talc pleurodesis and pleuroperitoneal shunting

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2898%2990294-3

7 January 2021

Symptomatic treatment of recurrent malignant pleural effusions with intrapleurally administered Corynebacterium parvum. Clinical response is not associated with evidence of enhancement of local cellular-mediated immunity.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2898%2990294-3

7 January 2021

Treatment of malignant ascitic and pleural effusion with Corynebacterium parvum

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2898%2990294-3

7 January 2021

Intrapleural tetracycline in malignant pleural effusions: A randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2898%2990294-3

7 January 2021

Tetracycline pleurodesis for malignant pleural effusions. A 10-year retrospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2898%2990294-3

7 January 2021

Intrapleural doxycycline control of malignant pleural effusions

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2898%2990294-3

7 January 2021

An assessment of the long-term results of controlling the reaccumulation of malignant effusions using intracavity bleomycin

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2898%2990294-3

7 January 2021

Comparison of OK-432 and mitomycin C pleurodesis for malignant pleural effusion caused by lung cancer. A Randomized Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2898%2990294-3

7 January 2021

Intrapleural therapy for malignant pleural effusions. A randomized comparison of bleomycin and tetracycline

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2898%2990294-3

7 January 2021

Intrapleural immunotherapy with escalating doses of interleukin-2 in metastatic pleural effusions

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2898%2990294-3

7 January 2021

Pleural Effusions: Pathophysiology and Management

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2898%2990294-3

7 January 2021

Diagnosis and management of malignant pleural effusions

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2898%2990294-3

7 January 2021

Intracavitary bleomycin and tetracycline in the management of malignant pleural effusions: a randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2898%2990294-3

7 January 2021

A comparison of intracavitary talc and tetracycline for the control of pleural effusions secondary to breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2898%2990294-3

7 January 2021

Comparison of intracavitary bleomycin and talc for control of pleural effusions secondary to carcinoma of the breast.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2898%2990294-3

7 January 2021

10.1016/S0954-6111(98)90294-3

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9692108%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

1 reference